410 related articles for article (PubMed ID: 16430874)
1. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
Rosenzweig-Lipson S; Zhang J; Mazandarani H; Harrison BL; Sabb A; Sabalski J; Stack G; Welmaker G; Barrett JE; Dunlop J
Brain Res; 2006 Feb; 1073-1074():240-51. PubMed ID: 16430874
[TBL] [Abstract][Full Text] [Related]
2. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
Dunlop J; Sabb AL; Mazandarani H; Zhang J; Kalgaonker S; Shukhina E; Sukoff S; Vogel RL; Stack G; Schechter L; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2005 May; 313(2):862-9. PubMed ID: 15705738
[TBL] [Abstract][Full Text] [Related]
3. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D
J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809
[TBL] [Abstract][Full Text] [Related]
4. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
[TBL] [Abstract][Full Text] [Related]
5. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
6. (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.
Booth RG; Fang L; Huang Y; Wilczynski A; Sivendran S
Eur J Pharmacol; 2009 Aug; 615(1-3):1-9. PubMed ID: 19397907
[TBL] [Abstract][Full Text] [Related]
7. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
Stark AD; Jordan S; Allers KA; Bertekap RL; Chen R; Mistry Kannan T; Molski TF; Yocca FD; Sharp T; Kikuchi T; Burris KD
Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines.
Welmaker GS; Nelson JA; Sabalski JE; Sabb AL; Potoski JR; Graziano D; Kagan M; Coupet J; Dunlop J; Mazandarani H; Rosenzweig-Lipson S; Sukoff S; Zhang Y
Bioorg Med Chem Lett; 2000 Sep; 10(17):1991-4. PubMed ID: 10987434
[TBL] [Abstract][Full Text] [Related]
9. Directly Observable Behavioral Effects of Lorcaserin in Rats.
Serafine KM; Rice KC; France CP
J Pharmacol Exp Ther; 2015 Dec; 355(3):381-5. PubMed ID: 26384326
[TBL] [Abstract][Full Text] [Related]
10. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
Cussac D; Newman-Tancredi A; Quentric Y; Carpentier N; Poissonnet G; Parmentier JG; Goldstein S; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):242-52. PubMed ID: 11882920
[TBL] [Abstract][Full Text] [Related]
11. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
[TBL] [Abstract][Full Text] [Related]
12. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.
Moya PR; Berg KA; Gutiérrez-Hernandez MA; Sáez-Briones P; Reyes-Parada M; Cassels BK; Clarke WP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1054-61. PubMed ID: 17337633
[TBL] [Abstract][Full Text] [Related]
13. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats.
Zaniewska M; McCreary AC; Przegaliński E; Filip M
Eur J Pharmacol; 2007 Oct; 571(2-3):156-65. PubMed ID: 17617403
[TBL] [Abstract][Full Text] [Related]
14. 5-HT2C receptor agonists attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
Nakai K; Nakae A; Oba S; Mashimo T; Ueda K
Eur J Pain; 2010 Nov; 14(10):999-1006. PubMed ID: 20488736
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
Knight AR; Misra A; Quirk K; Benwell K; Revell D; Kennett G; Bickerdike M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):114-23. PubMed ID: 15322733
[TBL] [Abstract][Full Text] [Related]
16. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
17. Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity.
Yang HY; Tae J; Seo YW; Kim YJ; Im HY; Choi GD; Cho H; Park WK; Kwon OS; Cho YS; Ko M; Jang H; Lee J; Choi K; Kim CH; Lee J; Pae AN
Eur J Med Chem; 2013 May; 63():558-69. PubMed ID: 23537943
[TBL] [Abstract][Full Text] [Related]
18. Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment.
Hietala J; Kuonnamäki M; Pälvimäki EP; Laakso A; Majasuo H; Syvälahti E
Psychopharmacology (Berl); 2001 Sep; 157(2):180-7. PubMed ID: 11594443
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.
Porter RH; Benwell KR; Lamb H; Malcolm CS; Allen NH; Revell DF; Adams DR; Sheardown MJ
Br J Pharmacol; 1999 Sep; 128(1):13-20. PubMed ID: 10498829
[TBL] [Abstract][Full Text] [Related]
20. Different regulation of rat 5-HT(2A) and rat 5-HT(2C) receptors in NIH 3T3 cells upon exposure to 5-HT and pipamperone.
Oekelen DV; Jurzak M; Van de Wiel D; Van Hecke G; Luyten WH; Leysen JE
Eur J Pharmacol; 2001 Aug; 425(1):21-32. PubMed ID: 11672571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
